Log In
BCIQ
Print this Print this
 

DX-4012

  Manage Alerts
Collapse Summary General Information
Company Shire plc
DescriptionHuman mAb against Factor XIIa
Molecular Target Factor XIIa
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationThrombosis
Indication DetailsTreat thrombosis
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$6,546.0M

$5,900.0M

$646.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/22/2016

$6,546.0M

$5,900.0M

$646.0M

Get a free BioCentury trial today